DEPDC1 and urinary bladder carcinoma: DEPDC1 is over-expressed in various cancers, especially in bladder cancer and a clinical trial using DEPDC1-derived short CTL epitope peptide-vaccination was performed for 6 patients with advanced bladder cancer [30-32], although the clinical response was marginal.